Skip to content
CNS Pulse
PipelineIndicationsCompaniesTargetsReadoutsConferencesAbstractsAuthors
  1. Home
  2. Pipeline
  3. Crenezumab
  4. MABT5102A

Development code · Biologic

MABT5102A

MABT5102A is a development code for Crenezumab, developed by AC Immune SA.

Status
Discontinued for Alzheimer's disease
Mechanism
Amyloid-beta (aggregated) Inhibitor
Developer
AC Immune SA

Programs

  • Crenezumab for Alzheimer's diseaseDiscontinuedDiscontinued

Also known as

  • RG7412
  • RG-7412
  • crenezumab

View the full Crenezumab profile →

CNS Pulse

© 2026 CNS Pulse · Psychopharmacology pipeline intelligence & conference reports.

Deal activity · Changelog